Article Text
Therapeutics
Randomised controlled trial
Intensive glucose lowering (HbA1c target<6.0%) for people with type 2 diabetes increases mortality
Statistics from Altmetric.com
Footnotes
-
Competing interests J Shaw has received lecturing fees, travel support and consultancy fees from Merck, Novartis, Pfizer, Novo Nordisk, Eli Lilly, Sanofi Aventis, Boehringer Ingelheim, Astra Zeneca, Bristol Myer Squibb.